Drug Type Antibody drug conjugate (ADC) |
Synonyms 重组HER2人源化单克隆抗体单甲基奥瑞他汀F偶联剂, FS-1502, IKS 014 + [4] |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | China | 28 Mar 2023 | |
Metastatic Colorectal Carcinoma | Phase 3 | China | 30 Jan 2023 | |
Non-Small Cell Lung Cancer | Phase 3 | China | 30 Jan 2023 | |
Stomach Cancer | Phase 3 | China | 30 Jan 2023 | |
Breast Cancer | Phase 3 | China | - | |
HER2-positive gastric cancer | Phase 2 | China | 08 Nov 2022 | |
HER2 Positive Solid Tumors | Phase 2 | China | 14 Jun 2022 | |
RAS/BRAF Wild Type HER2 Positive Colorectal Cancer | Phase 2 | China | 07 Jun 2022 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | China | 31 May 2022 | |
HER2 mutant non-small cell lung cancer | Phase 2 | China | 18 Mar 2022 |
NCT03944499 (Pubmed) Manual | Phase 1 | 150 | (HER2-expressing solid tumors (n = 5) and BC (n = 145)) | itdnynsnfn(eaxkcpsysn) = tovqmucutb ptsfkegoqa (xakcjdvosf ) View more | Positive | 17 Jun 2024 | |
(HER2-positive BC patients receiving the RP2D) | ohtksmysne(nowopbcruj) = cqanixcgwi vlyzxzvtke (hqasqujhnh ) View more | ||||||
Phase 1 | Advanced HER2-Positive Breast Carcinoma HER2 Positive | 70 | jvlojngzbj(xqyzelvpxt) = kesqjxaqky csbtkjeklu (vdmplfhcst, 40.45 - 65.17) View more | Positive | 26 May 2023 |